Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Beam Therapeutics Inc. before investing. In this article, we go over a few key ...

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in ...

Growth Drivers of The Gene Therapy Industry As per IMARC, the US gene therapy market size has been pegged at US$1,312.2 million in 2024. The market should reach US$3,697.8 million by 2033.

KLP Kapitalforvaltning AS purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) in the fourth ...

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have earned an average recommendation of “Buy” from the fourteen brokerages that are presently covering the company, Marketbeat reports ...

Beam Therapeutics Inc.’s BEAM share price has surged by 9.89%, which has investors questioning if this is right time to sell.

Beam Therapeutics (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin ...

Still, BEAM-302 has innovative in vivo base editing technology that could potentially offer a one-time curative therapy for patients suffering from AATD. BEAM has a long cash runway, and its ...

In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique ...

EDT Cathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics (BEAM) todayDon't Miss Our End of Quarter Offers: Discover the ...

Beam Therapeutics specializes in developing base-edited therapies for rare diseases and cancers. The company’s proprietary base editing platform allows for precise genetic modifications without ...

Also Read: Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity Initial safety and efficacy data from ...